114 related articles for article (PubMed ID: 8683875)
41. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
42. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
43. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
44. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis.
Lewis PJ; Salama A
J Nucl Med; 1994 Oct; 35(10):1647-9. PubMed ID: 7931664
[TBL] [Abstract][Full Text] [Related]
45. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer.
Kosuda S; Kison PV; Greenough R; Grossman HB; Wahl RL
Eur J Nucl Med; 1997 Jun; 24(6):615-20. PubMed ID: 9169567
[TBL] [Abstract][Full Text] [Related]
46. Multi-directional positron imaging: evaluation of cancer detection with 2-(F-18)-fluoro-2-deoxy-D-glucose.
Tadokoro M; Ota T; Kato T; Ito K; Ishigaki T; Amano M; Sakuma S
Radiat Med; 1992; 10(4):141-4. PubMed ID: 1410561
[TBL] [Abstract][Full Text] [Related]
47. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging?
Hoegerle S; Juengling F; Otte A; Altehoefer C; Moser EA; Nitzsche EU
Radiology; 1998 Oct; 209(1):253-8. PubMed ID: 9769840
[TBL] [Abstract][Full Text] [Related]
48. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
49. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
51. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
52. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.
Wahl RL; Zasadny K; Helvie M; Hutchins GD; Weber B; Cody R
J Clin Oncol; 1993 Nov; 11(11):2101-11. PubMed ID: 8229124
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
Kahn D; Follett KA; Bushnell DL; Nathan MA; Piper JG; Madsen M; Kirchner PT
AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
[TBL] [Abstract][Full Text] [Related]
54. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
[TBL] [Abstract][Full Text] [Related]
55. Detecting recurrent or residual lung cancer with FDG-PET.
Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
[TBL] [Abstract][Full Text] [Related]
56. Impact of attenuation correction on the accuracy of FDG-PET in patients with abdominal tumors: a free-response ROC analysis.
Hustinx R; Dolin RJ; Bénard F; Bhatnagar A; Chakraborty D; Smith RJ; Jang S; Alavi A
Eur J Nucl Med; 2000 Sep; 27(9):1365-71. PubMed ID: 11007519
[TBL] [Abstract][Full Text] [Related]
57. Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: a dynamic phantom study.
Raylman RR; Kison PV; Wahl RL
Eur J Nucl Med; 1999 Jan; 26(1):39-45. PubMed ID: 9933660
[TBL] [Abstract][Full Text] [Related]
58. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.
Avril N; Dose J; Jänicke F; Bense S; Ziegler S; Laubenbacher C; Römer W; Pache H; Herz M; Allgayer B; Nathrath W; Graeff H; Schwaiger M
J Clin Oncol; 1996 Jun; 14(6):1848-57. PubMed ID: 8656253
[TBL] [Abstract][Full Text] [Related]
59. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose.
Kole AC; Nieweg OE; van Ginkel RJ; Pruim J; Hoekstra HJ; Paans AM; Vaalburg W; Koops HS
Ann Surg Oncol; 1997 Jan; 4(1):57-63. PubMed ID: 8985518
[TBL] [Abstract][Full Text] [Related]
60. FDG-PET screening for cerebral metastases in patients with suspected malignancy.
Larcos G; Maisey MN
Nucl Med Commun; 1996 Mar; 17(3):197-8. PubMed ID: 8692485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
